期刊
AIDS
卷 20, 期 2, 页码 294-297出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.aids.0000199819.40079.e9
关键词
-
资金
- NIAID NIH HHS [N01-AI-05395] Funding Source: Medline
An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 X 10(7) \pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据